Status:
COMPLETED
Off Label Use of Propranolol for Infancy Hemangiomas
Lead Sponsor:
Hannover Medical School
Conditions:
Hemangioma
Eligibility:
All Genders
1-8 years
Brief Summary
Propranolol use for infancy hemangiomas is of world wide interest due to low cost and presumed efficacy. The investigators hypothesized that the drug ist highly active against growing hemangiomas in p...
Detailed Description
Treatment modalities: The investigators employed the "best-guess"-dose from the literature at 2 mg/kg/day divided into three daily oral administrations. Individualized capsules were manufactured from ...
Eligibility Criteria
Inclusion
- Infants with "problematic" true infantile hemangiomas (potentially disfiguring hemangiomas in the face, functional threatening hemangiomas of hands, feet, genitalia)\> 4 weeks and \< 8 months of age.
Exclusion
- "Uncomplicated" Hemangiomas (trunk, extremities), infants with heart disease, known arrhythmias, bronchoobstructive disease, known hypoglycaemia events.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01211080
Start Date
August 1 2008
End Date
October 1 2013
Last Update
November 11 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Surgery, Kinderkrankenhaus Bult
Hanover, Hannover, Germany, 30173
2
Pediatric Surgery, Hannover Medical School
Hanover, Lower Saxony, Germany, 30625
3
Kinderzentrum Klinikum Hildesheim
Hildesheim, Lower Saxony, Germany, 31134